The massive non-recurring IPR&D charge (~$79M) creates a one-time accounting loss but does not reflect ongoing cash burn. Focus on the combined entity's cash runway (~$39.4M pro forma) and the timing of the CY200 Phase 2 clinical trial application decision (expected early December 2026), which triggers the next PIPE tranche. The stockholder vote to enable Series C conversion is a key catalyst for share count clarity.
Price Chart
Executive Summary
Ensysce Biosciences filed an amended 8-K (8-K/A) providing unaudited pro forma financial information for its August 5, 2026 acquisition of Cy Biopharma. The transaction was accounted for as an asset acquisition, with substantially all of the ~$90.8 million purchase consideration allocated to in-process research and development (IPR&D) for Cy's lead candidate CY200, which was immediately expensed. Concurrently, Ensysce raised ~$21.5 million in a PIPE financing (with potential for an additional ~$30.4 million upon clinical milestones) and settled existing 3i LP financing arrangements. The combined entity's pro forma net loss for FY2025 was ~$91.6 million, reflecting the large non-recurring IPR&D charge.
Key Facts
- Ensysce acquired Cy Biopharma on August 5, 2026, issuing 282,122 shares of Series C Non-Voting Convertible Preferred Stock (convertible into 1,000 common shares each) as consideration.
- The acquisition was accounted for as an asset acquisition; ~$79 million of acquired IPR&D (CY200 program) was immediately expensed in the pro forma statement of operations for FY2025.
- Concurrent PIPE financing raised ~$21.5 million in gross proceeds at initial closing (66,811 Series C shares at $321.79/share).
- Potential additional PIPE tranches of ~$21.5 million (53,449 shares) and ~$8.9 million (22,166 shares) are contingent on a specified clinical trial milestone.
- All outstanding Series B Preferred Stock held by 3i, LP was converted into 3,229,276 common shares; 3i warrants were converted into 7,183 Series C shares; Ensysce paid 3i $250,000 cash.
- Pro forma combined cash as of June 30, 2026 was ~$39.4 million, including $21.5 million from the PIPE and $11.4 million from Cy convertible notes issued in July 2026.
- Pro forma net loss attributable to common stockholders for FY2025 was ~$91.6 million ($15.82 per share), driven by the ~$79 million IPR&D expense.
- Pro forma net loss for H1 2026 was ~$9.2 million ($0.70 per share), reflecting combined operating losses without the non-recurring IPR&D charge.
- Series C Preferred Stock is convertible into common stock only after stockholder approval; as of filing, approval had not been obtained.
- Potential dilution from Series C conversion: up to 358,292,000 common shares (282,122 merger shares + 66,811 PIPE shares + 7,183 3i shares + 2,176 Galephar shares, each convertible at 1,000:1).
Financial Impact
Non-recurring IPR&D expense of ~$79 million; pro forma FY2025 net loss of ~$91.6 million; pro forma H1 2026 net loss of ~$9.2 million; pro forma cash of ~$39.4 million as of June 30, 2026.
Risk Factors
- Massive potential dilution: Series C Preferred Stock is convertible into up to ~358 million common shares (subject to stockholder approval), which would massively dilute existing holders.
- The CY200 Phase 2 trial has not yet been approved by UK regulators (MHRA decision expected December 2026); failure to obtain approval or negative data would impair the value of the acquired asset.
- The PIPE's second tranche (~$21.5M) and Cy milestone tranche (~$8.9M) are contingent on a clinical milestone; if not achieved, Ensysce will have less cash than pro forma projections suggest.
- Ensysce has a history of operating losses and negative cash flows; the combined entity may require additional financing before reaching profitability.
- document contains text addressed to automated readers
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001493152-26-047317 |
| Exhibit: ex99-3.htm | 0001493152-26-047317 |
| Exhibit: ex99-4.htm | 0001493152-26-047317 |
| Exhibit: ex99-1.htm | 0001493152-26-047317 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | S-3 | $0.4500 $0.4499 | ▲ +0.02% | ▲ +0.58% | $0.4500 (+0.00%) |
Oct 15, 2026 12d ago | 8-K/A | $0.5183 $0.5029 | ▲ +2.97% | ▲ +3.39% | $0.4500 (+13.18%) |
Aug 25, 2026 9w ago | 8-K | $0.4120 $0.3990 | ▲ +3.16% | ▲ +3.81% | $0.4500 (−9.22%) |
Jun 29, 2026 17w ago | EFFECT | $0.2967 $0.2900 | ▲ +2.26% | ▲ +3.04% | $0.4500 (−51.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers